购物车摘要

购物车里还没有商品。

Osimertinib

SKU: orb1305406

描述

Osimertinib (AZD-9291) is an oral, irreversible third-generation EGFR inhibitor designed to target the T790M resistance mutation in non-small cell lung cancer (NSCLC). It is widely used in preclinical research, demonstrating potent antitumor activity in both in vitro cell assays and in vivo xenograft models of EGFR-mutant NSCLC.

研究领域

Cardiovascular Research, Pharmacology & Drug Discovery, Signal Transduction

图片与验证

−

关键属性

−
CAS 号1421373-65-0
MW499.6
纯度>98%
分子式C28H33N7O2
SMILESCN1C=C(C=2C1=CC=CC2)C3=NC(NC4=C(OC)C=C(N(CCN(C)C)C)C(NC(C=C)=O)=C4)=NC=C3
靶点Kinase
溶解性Soluble in DMSO (up to 40 mg/ml)

客户验证数据

−
以下数据由各地研究人员提交。即使我们尚未自行检测,这些结果也有助于判断该产品是否适合您的应用或种属。
按应用统计成功数
反应性分布

最新实验

5 Results
稀释
样本
摘要
In vitro
Human
-
Recombinant human PDI protein (in vitro) and U2OS human osteosarcoma cells (cellular assays).
Osimertinib was used as a reference/control...
In vitro, In vivo
Human, Mouse
In vitro: 0 to 10 μM. In vivo: 20 mg/kg.
Human (cell lines) and Mouse (xenograft host)
Osimertinib was used both in vitro...
In vitro
Human
-
Human renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) cell lines (769-P, SW839, A549, H1299) and their TKI-resistant derivatives.
Osimertinib was used as a control...
In vitro
Mouse
0, 0.01, 0.1, and 1 μM
Mouse Ba/F3 (pro-B cells) and NIH/3T3 (fibroblasts) stably transfected with human EGFR L858R/T790M/L792H or L858R/T790M/G796R triple mutations
Osimertinib was used as a reference/control...
In vitro
Human, Mouse
In virto: 0.25 Μm and 2.7–3.3 μM. In vivo: In vivo: 10 mg/kg
Human (cell lines) and Mouse (xenograft host)
Osimertinib was used as the third-generation...

生物活性

−
靶点 IC50
MNK2:48.6 nM|EGFR (WT):493.8 nM|MNK1:324 nM|H1975 cells:1.78 μM|PC9 cells:0.66 μM|EGFR (exon 19 deletion):12.92 nM|EGFR (L858R/T790M):11.44 nM
体内
In mutant EGFR cell lines, AZD9291 effectively inhibits cell proliferation.
体外
In the EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models, oral administration of AZD9291 (5 mg/kg) effectively inhibits AKT and ERK signaling pathways as well as EGFR phosphorylation in tumors, leading to tumor regression.
细胞研究
AZD-9291 is dissolved in DMSO and stored, and then diluted with appropriate medium before use. PC-9 cells are seeded into T75 flasks (5×105 cells/flask) in RPMI growth media and incubated at 37°C, 5% CO2. The following day the media is replaced with media supplemented with a concentration of EGFR inhibitor equal to the EC50 concentration predetermined in PC-9 cells. Media changes are carried out every 2-3 days and resistant clones allowed to grow to 80% confluency prior to the cells being trypsinised and reseeded at the original seeding density in media containing twice the concentration of EGFR inhibitor. Dose escalations are continued until a final concentration of 1.5 μM Gefitinib, 1.5 μM Afatinib, 1.5 μM WZ4002 or 160 nM AZD-9291 are achieved.

储存与操作

−
储存-20°C
有效期12 months from date of receipt.
免责声明For research use only

别名

−
AZD-9291

相似产品

−
  • AZD 4205 [orb573442]

    >98%

    2091134-68-6

    521.601

    C25H31N9O2

    250 mg, 100 mg, 1 g
  • Osimertinib dimer [orb3135414]

    2564638-97-5

    1000.22

    C56H67N14O4

    50 mg, 10 mg
  • ER ligand-14 [orb3210103]

    10 mg, 50 mg
  • SG-55 [orb3211209]

    10 mg, 50 mg
  • ER ligand-14-PEG3-Boc [orb3177173]

    50 mg, 10 mg
质量保证

质量保证

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our 条款与条件和选购指南.

关键属性

−
暂无计算属性。

实验方案信息

可选规格

请在下方选择规格

10 mg
¥ 2,210.00
50 mg
¥ 3,770.00
发货Usually dispatched within 5-10 working days
批量询价